43.95
0.46 (1.06%)
| Penutupan Terdahulu | 43.49 |
| Jumlah Dagangan | 681,399 |
| Harga / Pendapatan (P/E Ke hadapan) | 38.17 |
| Harga / Jualan (P/S) | 11.40 |
| Harga / Buku (P/B) | 19.27 |
| Julat 52 Minggu |
| Margin Keuntungan | -150.68% |
| Margin Operasi (TTM) | -182.26% |
| EPS Cair (TTM) | -3.01 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 481.07% |
| Nisbah Semasa (MRQ) | 5.65 |
| Aliran Tunai Operasi (OCF TTM) | -107.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.76 M |
| Pulangan Atas Aset (ROA TTM) | -29.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | UroGen Pharma Ltd. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.06 |
|
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.87% |
| % Dimiliki oleh Institusi | 105.32% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SCHOENBERG MARK | - | 43.82 | -871 | -38,163 |
| SMITH JASON DREW | - | 43.82 | -1,519 | -66,555 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,390 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -104,718 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 43.82 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SMITH JASON DREW | Pegawai | 08 Sep 2026 | Jual (-) | 1,519 | 43.82 | 66,555 |
| SCHOENBERG MARK | Pegawai | 08 Sep 2026 | Jual (-) | 871 | 43.82 | 38,163 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |